Premier Fund Managers Ltd cut its holdings in Vericel Co. (NASDAQ:VCEL - Free Report) by 40.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,705 shares of the biotechnology company's stock after selling 7,383 shares during the period. Premier Fund Managers Ltd's holdings in Vericel were worth $592,000 as of its most recent filing with the SEC.
Several other institutional investors have also made changes to their positions in the stock. Arcadia Investment Management Corp MI bought a new stake in shares of Vericel during the 4th quarter valued at about $48,000. Smartleaf Asset Management LLC increased its position in shares of Vericel by 511.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company's stock valued at $70,000 after purchasing an additional 1,058 shares during the last quarter. Geneos Wealth Management Inc. raised its position in Vericel by 826.6% in the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company's stock worth $138,000 after acquiring an additional 2,240 shares during the period. Quantbot Technologies LP purchased a new position in Vericel in the third quarter valued at approximately $146,000. Finally, KBC Group NV grew its stake in shares of Vericel by 82.5% during the 4th quarter. KBC Group NV now owns 2,707 shares of the biotechnology company's stock worth $149,000 after acquiring an additional 1,224 shares during the period.
Analyst Ratings Changes
A number of research firms have recently commented on VCEL. Stephens restated an "overweight" rating and set a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. Canaccord Genuity Group boosted their price target on shares of Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Vericel in a report on Friday, February 28th. Truist Financial restated a "buy" rating and set a $61.00 price target (down previously from $67.00) on shares of Vericel in a report on Monday, March 3rd. Finally, StockNews.com upgraded shares of Vericel from a "sell" rating to a "hold" rating in a research report on Saturday, March 8th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $62.29.
Check Out Our Latest Analysis on VCEL
Vericel Trading Down 3.4 %
Shares of VCEL stock traded down $1.53 during trading hours on Tuesday, reaching $43.09. 284,507 shares of the stock were exchanged, compared to its average volume of 378,054. The company's 50-day moving average price is $52.94 and its 200-day moving average price is $51.79. Vericel Co. has a 12-month low of $39.12 and a 12-month high of $63.00. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of 719.74 and a beta of 1.78.
Insider Transactions at Vericel
In related news, CEO Dominick Colangelo sold 26,592 shares of Vericel stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $45.78, for a total value of $1,217,381.76. Following the completion of the transaction, the chief executive officer now directly owns 259,997 shares in the company, valued at approximately $11,902,662.66. This trade represents a 9.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jonathan Siegal sold 1,092 shares of Vericel stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total value of $67,693.08. Following the sale, the insider now directly owns 1,206 shares of the company's stock, valued at $74,759.94. This trade represents a 47.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,092 shares of company stock valued at $1,683,582. Corporate insiders own 5.20% of the company's stock.
Vericel Company Profile
(
Free Report)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Read More
Before you consider Vericel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vericel wasn't on the list.
While Vericel currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
